- Home
- CNS vs PTGX Comparison
CNS vs PTGX Comparison
Compare CNS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNS
- PTGX
- Stock Information
- Founded
- CNS 1986
- PTGX 2006
- Country
- CNS United States
- PTGX United States
- Employees
- CNS N/A
- PTGX N/A
- Industry
- CNS Investment Managers
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CNS Finance
- PTGX Health Care
- Exchange
- CNS Nasdaq
- PTGX Nasdaq
- Market Cap
- CNS 3.9B
- PTGX 3.7B
- IPO Year
- CNS 2004
- PTGX 2016
- Fundamental
- Price
- CNS $70.38
- PTGX $58.38
- Analyst Decision
- CNS Hold
- PTGX Strong Buy
- Analyst Count
- CNS 3
- PTGX 9
- Target Price
- CNS $81.67
- PTGX $70.44
- AVG Volume (30 Days)
- CNS 253.2K
- PTGX 915.6K
- Earning Date
- CNS 10-15-2025
- PTGX 11-06-2025
- Dividend Yield
- CNS 3.46%
- PTGX N/A
- EPS Growth
- CNS 23.33
- PTGX N/A
- EPS
- CNS 3.15
- PTGX 0.80
- Revenue
- CNS $543,579,000.00
- PTGX $209,180,000.00
- Revenue This Year
- CNS $7.32
- PTGX N/A
- Revenue Next Year
- CNS $8.15
- PTGX $185.11
- P/E Ratio
- CNS $22.76
- PTGX $72.62
- Revenue Growth
- CNS 11.54
- PTGX N/A
- 52 Week Low
- CNS $68.99
- PTGX $33.31
- 52 Week High
- CNS $110.67
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- CNS 39.40
- PTGX 53.07
- Support Level
- CNS $70.02
- PTGX $54.50
- Resistance Level
- CNS $72.50
- PTGX $60.40
- Average True Range (ATR)
- CNS 1.56
- PTGX 2.68
- MACD
- CNS -0.23
- PTGX -0.12
- Stochastic Oscillator
- CNS 4.96
- PTGX 52.50
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.